drugset
drugset / Trial / NCT03910842

Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy

NCT03910842 ↗

Phase 0 Unknown 12 enrolled Timmune Biotech Inc. Hunan Provincial People's Hospital · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a single arm, open-label, early phase Ⅰ study, to determine the safety and efficacy of CD19-TriCAR-T and CD19-TriCAR-SILK cell therapy in Children CD19+ Leukemia Non-Hodgkin lymphoma treatment.

Timeline

Start
2019-03-21
Primary completion
2022-04-15
Completion
2022-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject CD19-TriCAR-SILK Cell therapy — Intravenous
Subject CD19-TriCAR-T Cell therapy — Intravenous

Indications

leukemia non-Hodgkin lymphoma